摘要
目的:探讨替罗非班在急性ST段抬高型心肌梗死(STEMI)急诊PCI术前应用的安全性和效果。方法:选取来我院行STEMI急诊PCI治疗的患者120例,将其随机分为观察组(三联抗血小板组)和对照组(双联抗血小板组),每组各60例。对照组患者于术前均嚼服600mg氯吡格雷和300mg阿司匹林,观察组患者于术前均嚼服300mg氯吡格雷、300mg肠溶阿司匹林联合替罗非班。比较两组患者的术后应用抽吸导管、TIMI血流分级、MBG分级、左室功能指标和校正TIMI帧数。结果:观察组和对照组患者术后应用抽吸导管、TIMI血流分级和MBG分级相比较,数据差异明显,有统计学意义(P均<0.05)。观察组和对照组患者术后左室功能指标和TIMI帧数相比较,数据差异明显,有统计学意义(P均<0.05)。结论:替罗非班在STEMI急诊PCI术前的应用效果良好,能有效减少缺血事件,改善患者心功能,安全有效。
Objective：To observe the safety and effect of tirofiban administered before an emergency per- cutaneous coronary intervention （PCI） for patients with acute ST-elevation myocardial infarction （STEMI）. Methods：120 patients with STEMI admitted to our hospital underwent emergent PCI, and were randomly divided into observation group and control group, 60 cases in each group. The two groups were compared regarding the application of aspiration catheter, TIMI flow grade, MBG grade, left ventricular function index and corrected TIMI frame count. Results： The application of aspiration catheter, TIMI flow grade and MBG grade in two groups showed statistically significant difference （P〈0.05）. The left ventricular function and TIMI frame count in two groups showed statistically significant difference （P〈0.05）. Conclusions： Tirofiban can be safely administered before the PCI for patients with acute STEMI, and pre-PCI administration of this agent can boost the cardiac function and reducing the cardiovascular complications.
出处
《陕西医学杂志》
CAS
2015年第8期959-961,共3页
Shaanxi Medical Journal
